Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan
Most patients with severe CKD received RDV immediately after hospitalization. The majority of patients recovered by 28 days. The study provided insights into RDV treatment in inpatient settings, which could contribute to the discussion on standard of care in this population in Japan.
Authors
- Manami Yoshida (ORCID: https://orcid.org/0000-0002-4454-4654)
- Mazin Abdelghany (ORCID: https://orcid.org/0000-0001-5192-8659)
- Yi Piao (ORCID: https://orcid.org/0009-0008-3162-543X)
- Nao Taguchi
- Rikisha Gupta (ORCID: https://orcid.org/0000-0001-9784-416X)
- Hiroshi Yotsuyanagi (ORCID: https://orcid.org/0000-0001-7882-5262)
- Mel Chiang
- Mark Berry (ORCID: https://orcid.org/0000-0002-8534-2012)
- Jami Peters
- Chenyu Wang (ORCID: https://orcid.org/0000-0002-3675-3616)
Institutions
- YKK (Japan) (JP)
- Gilead Sciences (United States) (US)
- The University of Tokyo (JP)
Publication Details
- Journal
- Clinical and Experimental Nephrology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1007/s10157-024-02609-0
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- John Jay College of Criminal Justice